人类微生物组:新批准的治疗对C. difficile感染的影响
Christopher M Bland1, Bryan L Love2, Bruce M Jones3
1University of Georgia College of Pharmacy, Savannah, GA, USA.
概括
活微生物组治疗为复发性Clostridioides difficile感染 (CDI) 提供了一个有希望的解决方案. 最近获得FDA批准的活生物治疗产品 (LBPs) 与便微生物群移植 (FMT) 相比,在预防CDI复发方面具有优势.
科学领域:
- 微生物组研究的研究.
- 传染病治疗药物 传染病治疗药物
- 胃肠病学 胃肠病学
背景情况:
- 复发性Clostridioides difficile感染 (CDI) 是一个重大的临床挑战,影响患者的生活质量.
- 便微生物群移植 (FMT) 对复发性CDI有好处,但存在风险,并未获得FDA的批准.
研究的目的:
- 审查微生物群在健康和疾病中的作用.
- 讨论活生生的微生物体,它们的特征和结果数据.
- 探索将这些药物整合到临床实践中的考虑因素.
主要方法:
- 关于微生物组代理和Clostridioides difficile感染的现有文献的综述.
- 对已批准的活微生物组产品的结果数据和特征进行分析.
- 讨论监管状况和临床整合挑战.
主要成果:
- 美国食品和药物管理局 (FDA) 已批准两种活生物疗法产品 (LBPs) 用于预防成人复发性CDI.
- 这些LBP代表了一种新的治疗类别,提供标准化的制造和生物体量,与FMT不同.
- 登记试验表明,这些药物在预防CDI复发方面具有有效性,尽管它们在施用途径上有所不同.
结论:
- 活微生物组疗法是治疗复发性CDI的一个有希望的方法.
- 需要对不同种群进行进一步的研究和现实世界的证据来为临床指南提供信息.
- 成本和后勤因素仍然是这些新疗法的广泛采用障碍.
相关概念视频
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
111
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
01:17Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146